AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.āāā ā
Healthcare
Biotechnology
1 years
USD
Exclusive to Premium users
$1.28
Price+0.79%
$0.01
$34.977m
Small
-
Premium
Premium
-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin$0.00
-
1y CAGR-
3y CAGR-
5y CAGR-$37.380m
-
1y CAGR-
3y CAGR-
5y CAGR-$1.24
-
1y CAGR-
3y CAGR-
5y CAGR$68.842m
$75.825m
Assets$6.983m
Liabilities-
Debt0.00%
-
Debt to EBITDA-$35.503m
-
1y CAGR-
3y CAGR-
5y CAGR